Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Novel therapies for multiple myeloma include the immunomodulatory drugs lenalidomide and thalidomide and the proteasome inhibitor bortezomib, which have increased response rates and survival times. However, the agents can cause myelosuppression, which, if not managed effectively, can be life threatening and interfere with optimal therapy and quality of life. The International Myeloma Foundation's Nurse Leadership Board developed a consensus statement that includes toxicity grading, strategies for monitoring and managing myelosuppression associated with novel therapies, and educational recommendations for patients and their caregivers. Although anemia, neutropenia, and thrombocytopenia are expected side effects of novel therapies for multiple myeloma, they are manageable with appropriate interventions and education.
Miceli
Teresa
T
Mayo Medical Center, Rochester, MN, USA. miceli.teresa@mayo.edu
Colson
Kathleen
K
Gavino
Maria
M
Lilleby
Kathy
K
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001772:Blood Cell Count; D001853:Bone Marrow / Q000187:drug effects*; D032921:Consensus; D006801:Humans; D007857:Leadership; D009101:Multiple Myeloma / Q000188:drug therapy*; D012956:Societies, Nursing
D000970:Antineoplastic Agents